ShanXi C&Y Pharmaceutical Group Co.,LTD.

SZSE:300254 Stock Report

Market Cap: CN¥2.0b

ShanXi C&Y Pharmaceutical GroupLTD Past Earnings Performance

Past criteria checks 2/6

ShanXi C&Y Pharmaceutical GroupLTD's earnings have been declining at an average annual rate of -5.8%, while the Pharmaceuticals industry saw earnings growing at 9.2% annually. Revenues have been declining at an average rate of 7.9% per year. ShanXi C&Y Pharmaceutical GroupLTD's return on equity is 8.8%, and it has net margins of 5.7%.

Key information

-5.8%

Earnings growth rate

-4.3%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate-7.9%
Return on equity8.8%
Net Margin5.7%
Last Earnings Update31 Mar 2024

Recent past performance updates

ShanXi C&Y Pharmaceutical Group (SZSE:300254) Strong Profits May Be Masking Some Underlying Issues

Mar 25
ShanXi C&Y Pharmaceutical Group (SZSE:300254) Strong Profits May Be Masking Some Underlying Issues

Recent updates

ShanXi C&Y Pharmaceutical Group Co.,LTD.'s (SZSE:300254) 36% Price Boost Is Out Of Tune With Revenues

May 27
ShanXi C&Y Pharmaceutical Group Co.,LTD.'s (SZSE:300254) 36% Price Boost Is Out Of Tune With Revenues

ShanXi C&Y Pharmaceutical Group (SZSE:300254) Strong Profits May Be Masking Some Underlying Issues

Mar 25
ShanXi C&Y Pharmaceutical Group (SZSE:300254) Strong Profits May Be Masking Some Underlying Issues

ShanXi C&Y Pharmaceutical Group Co., Ltd.'s (SZSE:300254) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Mar 06
ShanXi C&Y Pharmaceutical Group Co., Ltd.'s (SZSE:300254) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Revenue & Expenses Breakdown

How ShanXi C&Y Pharmaceutical GroupLTD makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SZSE:300254 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 248064644353
31 Dec 237992545350
30 Sep 23767-10746557
30 Jun 23790-12049255
31 Mar 23820-11951454
01 Jan 23829-11953555
30 Sep 22847-11155452
30 Jun 22878-11057753
31 Mar 22899-9458557
01 Jan 22930-9159957
30 Sep 21966-14465172
30 Jun 21911-19165777
31 Mar 21920-21870572
31 Dec 20848-26269872
30 Sep 20861-16270457
30 Jun 20968-11276749
31 Mar 201,029-5878247
31 Dec 191,132581849
30 Sep 191,1842981543
30 Jun 191,1543277250
31 Mar 191,1192074055
31 Dec 181,136774854
30 Sep 181,0922071862
30 Jun 181,0581867370
31 Mar 181,0242363154
31 Dec 179392255743
30 Sep 178912551326
30 Jun 17834314850
31 Mar 17791304570
31 Dec 16746304380
30 Sep 16732224430
30 Jun 16704244270
31 Mar 16683224160
31 Dec 15684234090
30 Sep 15669403880
30 Jun 15666403890
31 Mar 15660413850
31 Dec 14654413830
30 Sep 14646383610
30 Jun 14598333290
31 Mar 14547292950
31 Dec 13514272770
30 Sep 13429292360
30 Jun 13415272250

Quality Earnings: 300254 has a large one-off gain of CN¥37.1M impacting its last 12 months of financial results to 31st March, 2024.

Growing Profit Margin: 300254 became profitable in the past.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 300254 has become profitable over the past 5 years, growing earnings by -5.8% per year.

Accelerating Growth: 300254 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: 300254 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.8%).


Return on Equity

High ROE: 300254's Return on Equity (8.8%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.